Daniel Flicker 

Daniel is an Associate at Novo Ventures, the healthcare-focused venture capital arm of the Novo Nordisk Foundation. In this role, he is responsible for identifying and evaluating investment opportunities in therapeutics, medtech, and digital health, primarily focusing on preclinical or early clinical-stage private companies. He is also involved in portfolio company oversight, and works closely with management teams to evaluate and align on near-term strategic goals. Daniel was previously an Associate in healthcare investment banking at Chardan, where he originated and executed capital raises for pre-commercial life sciences companies. He also spent time on Chardan’s equity research team, where his coverage focused on disruptive platforms in genetic medicines. Prior to Chardan, Daniel worked at L.E.K. Consulting in the Life Sciences & Pharma practice.

Daniel holds a Ph.D. in Systems Biology from Harvard University and a B.A. in Biochemistry from Columbia University.